Preclinical evaluation of the antitumor activity of bortezomib in combination with vitamin C or with epigallocatechin gallate, a component of green tea.
about
Why bortezomib cannot go with 'green'?Effect of Tea Polyphenol Compounds on Anticancer Drugs in Terms of Anti-Tumor Activity, Toxicology, and PharmacokineticsAscorbic acid kills Epstein-Barr virus positive Burkitt lymphoma cells and Epstein-Barr virus transformed B-cells in vitro, but not in vivo.Current limitations of murine models in oncology for ascorbate research.Intravenous Vitamin C and Cancer: A Systematic Review.Association between Dietary Vitamin C Intake and Risk of Prostate Cancer: A Meta-analysis Involving 103,658 Subjects.Targeting tumor ubiquitin-proteasome pathway with polyphenols for chemosensitization.EGCG antagonizes Bortezomib cytotoxicity in prostate cancer cells by an autophagic mechanismIntegrating dietary supplements into cancer care.Synthesis and pharmacology of proteasome inhibitors.Synergistic enhancement of anticancer effects on numerous human cancer cell lines treated with the combination of EGCG, other green tea catechins, and anticancer compounds.Molecular characterization of the boron adducts of the proteasome inhibitor bortezomib with epigallocatechin-3-gallate and related polyphenols.EGCG enhances the efficacy of cisplatin by downregulating hsa-miR-98-5p in NSCLC A549 cells.Boschniakia Rossica Polysaccharide Triggers Laryngeal Carcinoma Cell Apoptosis by Regulating Expression of Bcl-2, Caspase-3, and P53.Pharmacologic Ascorbate in Myeloma Treatment: Doses Matter.Proteasome and heat shock protein 70 (HSP70) inhibitors as therapeutic alternative in multiple myeloma.The Use of a Brochure to Enable CAM-with-Chemotherapy Patient Education.
P2860
Q24630709-40F0346B-A7B6-437F-8652-BDA7EB6F6A0FQ28072731-141D98E9-CDB3-4B63-847E-D69A4B774EACQ33748089-E6678264-AEA9-4637-8FFB-90F52D57F275Q34336161-21B074DA-C0EF-4A4C-9118-88AAA014D6CCQ35175163-1B59AAF1-C0A6-482E-85F6-7EFAF5A9AC83Q35942208-09DB9A68-025E-4D73-9842-7AD896950A4BQ36037180-4CBEBDAA-AD7B-4199-9AD0-1A57EDFF57E7Q36168253-BB3AF5FA-A855-4668-84A4-EA76C650121AQ38084539-44BEE49D-FE8B-4C94-9DE0-C0584AE7C890Q38092777-E1A97D4E-D2E7-4D62-BDAA-1446623425B9Q38302024-C9C88C24-1321-4AAA-B219-43B847577F2AQ38911003-F4810AE0-AB74-4068-A102-98CDCC635DE6Q39006577-C0FFB232-BD80-4F15-B749-D278B0D2E115Q42103858-8A7F985D-EF5F-44C3-A64F-DEB4E58E3425Q42150701-F258E72F-F3AE-431D-B9F2-EA6BE556DCCCQ49569621-E491D9FA-5F59-4530-8EB6-118DB3C32187Q53086914-BF3EA094-6CC6-403F-9CE8-1BA6693E8016
P2860
Preclinical evaluation of the antitumor activity of bortezomib in combination with vitamin C or with epigallocatechin gallate, a component of green tea.
description
2011 nî lūn-bûn
@nan
2011 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի մարտին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
Preclinical evaluation of the ...... ate, a component of green tea.
@ast
Preclinical evaluation of the ...... ate, a component of green tea.
@en
type
label
Preclinical evaluation of the ...... ate, a component of green tea.
@ast
Preclinical evaluation of the ...... ate, a component of green tea.
@en
prefLabel
Preclinical evaluation of the ...... ate, a component of green tea.
@ast
Preclinical evaluation of the ...... ate, a component of green tea.
@en
P2093
P2860
P1476
Preclinical evaluation of the ...... ate, a component of green tea.
@en
P2093
Allison Berger
Bret Bannerman
Christopher Claiborne
Christopher Tsu
Erik Kupperman
Johan Monbaliu
Joseph Bolen
Lawrence Dick
P2860
P2888
P304
P356
10.1007/S00280-011-1591-2
P577
2011-03-13T00:00:00Z